Related Experiment Videos

Cyclo-oxygenase 2 inhibition in colorectal cancer therapy

R D Church1, J W Fleshman, H L McLeod

  • 1Department of Surgery, Washington University School of Medicine, 660 South Euclid Avenue, Campus Box 8069, St Louis, MO 63110-1093, USA. churchr@msnotes.wustl.edu

Abstract

Insights

Cyclo-oxygenase-2 (Cox-2) inhibitors show promise for treating and preventing colorectal cancer. Further clinical trials are needed to confirm their role in cancer therapy and prevention.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Renewed interest in cyclo-oxygenase inhibition for colorectal neoplasia treatment.
  • Discovery of cyclo-oxygenase (Cox) 2 and development of specific Cox-2 inhibitors.
  • Implications for colorectal cancer prevention and treatment.

Purpose of the Study:

  • To review the role of Cox-2 inhibition in colorectal neoplasia.
  • To explore the potential of Cox-2 inhibitors in cancer therapy.

Main Methods:

  • Medline database search using keywords: "colonic, colon or rectal and neoplasia or cancer" and "cyclo-oxygenase or Cox-2."
  • Inclusion of cross-references from relevant historical papers.

Main Results:

  • Substantial evidence indicates Cox-2 involvement in colorectal cancer development and progression.
  • Specific Cox-2 inhibition demonstrated efficacy in inhibiting cancer growth in vitro and in vivo models.
  • Mechanisms of action remain poorly understood; clinical applications are under investigation.

Conclusions:

  • Cox-2 inhibitors hold significant promise as adjuncts to current cancer treatments.
  • Need for randomized clinical trials to establish their role in chemoprevention, recurrence prophylaxis, and adjuvant therapy.
  • Potential application in colorectal and other solid tumors.

Related Concept Videos